Reuters logo
BRIEF-Kadimastem signs memorandum of understanding with Corestem
December 7, 2016 / 2:50 PM / a year ago

BRIEF-Kadimastem signs memorandum of understanding with Corestem

Dec 7 (Reuters) - Corestem Inc:

* Kadimastem Ltd - announced signing of memorandum of understanding with Korean company Corestem, for broad strategic collaboration between companies

* Kadimastem - Corestem to be granted exclusive license for commercialization of company’s ALS, diabetes products in Asia-Pacific region

* Kadimastem - Kadimastem will become a shareholder of Corestem by investing $1m in a similar investment mechanism

* Kadimastem - under collaboration agreement, companies will conduct clinical trials on Kadimastem’s product, astrorx, in Korea and Asia-Pacific region

* Kadimastem - upon signing final agreement, Corestem will invest $7m in Kadimastem

* Kadimastem - company plans to commence its phase I/IIA clinical trial (safety and efficacy of product in humans) in mid-2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below